Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    64
  • sponsor
    Hansa Biopharma AB
Updated on 4 October 2022

Summary

An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care

Description

After being informed about the study and potential risks, all patients giving written informed consent will undergo pre-screening to determine eligibility for study entry.

Once an organ offer is received, a virtual crossmatch (vXM) is performed. If the crossmatch is considered predictive of a positive flow cytometry crossmatch (FCXM), the patient will be evaluated if eligible to receive the desensitization currently in use at the study site. Subsequently the patient will be randomized in a 1:1 ratio to the imlifidase or the control arm.

If the patient is randomized to the imlifidase arm, the organ will be accepted and shipped, and the patient will proceed to imlifidase treatment (generally within 24 h prior to transplantation) followed by transplantation. If the patient is randomized to the control arm, transplantation made possible by the local desensitization regimen will occur. If the institution-specific desensitization protocol is deemed not to be successful, the organ offer will be turned down, and the patient will remain active on the waiting list and remain in the trial, while the kidney will be allocated to another recipient through the kidney allocation system (KAS).

All transplanted patients will receive induction therapy and maintenance immunosuppression. All patients will be followed for 12 months.

Estimated glomerular filtration rate (eGFR) will be assessed 12 months after randomization as the primary endpoint reasonably likely to predict a clinical benefit in patient survival.

All patients with donor specific antibodies (DSA) are at risk of developing antibody-mediated rejection (AMR). Imlifidase removes DSA quickly and efficiently at the time of transplantation but, as with other desensitization methods, the antibodies are expected to re-occur after transplantation. In the imlifidase treatment arm, and for desensitized control arm patients, protocol kidney biopsies will be performed at the time of transplantation and at 1 year after transplantation.

Details
Condition Kidney Transplantation in Highly Sensitized Patients
Treatment IVIG, Eculizumab, Imlifidase, PLEX, Anti-CD20 antibodies, Remain on wait list
Clinical Study IdentifierNCT04935177
SponsorHansa Biopharma AB
Last Modified on4 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Signed Informed Consent obtained before any trial-related procedures
Male or female age 18-70 years at the time of screening
Chronic kidney disease (CKD) stage 5, highly sensitized as evaluated by standard selection criteria, and active on the OPTN waiting list for a DD kidney transplant
Original calculated panel reactive antibody (cPRA) ≥99.9%
Virtual crossmatch (vXM), predictive of a positive crossmatch to an available deceased donor (DD)
Willingness and ability to comply with the protocol
Willingness to participate in the planned 4-year extension trial

Exclusion Criteria

High dose IVIg (2 g/kg) treatment within 28 days prior to imlifidase treatment
Previous treatment with imlifidase
Breast feeding or pregnancy
Women of child-bearing potential not willing or able to practice FDA-approved forms of contraception, or abstinence. Two medically acceptable methods of highly effective contraception must be used for the duration of the study (e.g. oral, transdermal, intravaginal, injectable or implantable contraceptive; intrauterine device; intrauterine hormone-releasing system; vasectomized partner; bilateral tubal occlusion; or double barrier method). For a woman to be considered postmenopausal this ascertainment must be made according to medical records and clinical history and may be aided by measurement of elevated postmenopausal serum gonadotropin levels (FSH)
ABO blood group incompatible transplantations (A2 or A2B kidneys will not be accepted for B recipients)
Positive serology for human immunodeficiency virus (HIV)
Clinical signs of hepatitis B virus (HBV) or hepatitis C virus (HCV) infections
Clinical signs of cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infections
Positive test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (according to local hospital routines)
Active tuberculosis
Severe other conditions requiring treatment and close monitoring, e.g. cardiac failure ≥grade 4 (New York Heart Association), unstable coronary disease or oxygen dependent chronic obstructive pulmonary disease (COPD)
Any condition that in the view of the Investigator precludes transplantation
History of a proven hypercoagulable condition
Present or history of thrombotic thrombocytopenic purpura (TTP), or known familial history of TTP
Intake of investigational drugs within 5 half-lives of the drug or 3 months, whichever is the longest
Contemporaneous participation in a medical device study
Known mental incapacity or language barriers precluding adequate understanding of the Informed Consent information and the trial activities
Inability by the judgement of the investigator to participate in the trial for any other reason
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note